Immunotherapy of Sepsis: Blind Alley or Call for Personalized Assessment?

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11110%2F17%3A10362033" target="_blank" >RIV/00216208:11110/17:10362033 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00023884:_____/12:00007422 RIV/00064190:_____/17:N0000070

Výsledek na webu

<a href="http://dx.doi.org/10.1007/s00005-016-0415-9" target="_blank" >http://dx.doi.org/10.1007/s00005-016-0415-9</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1007/s00005-016-0415-9" target="_blank" >10.1007/s00005-016-0415-9</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Immunotherapy of Sepsis: Blind Alley or Call for Personalized Assessment?

Popis výsledku v původním jazyce

Sepsis is the most frequent cause of death in noncoronary intensive care units. In the past 10 years, progress has been made in the early identification of septic patients and their treatment. These improvements in support and therapy mean that mortality is gradually decreasing, however, the rate of death from sepsis remains unacceptably high. Immunotherapy is not currently part of the routine treatment of sepsis. Despite experimental successes, the administration of agents to block the effect of sepsis mediators failed to show evidence for improved outcome in a multitude of clinical trials. The following survey summarizes the current knowledge and results of clinical trials on the immunotherapy of sepsis and describes the limitations of our knowledge of the pathogenesis of sepsis. Administration of immunomodulatory drugs should be linked to the current immune status assessed by both clinical and molecular patterns. Thus, a careful daily review of the patient&apos;s immune status needs to be introduced into routine clinical practice giving the opportunity for effective and tailored use of immunomodulatory therapy.

Název v anglickém jazyce

Immunotherapy of Sepsis: Blind Alley or Call for Personalized Assessment?

Popis výsledku anglicky

Sepsis is the most frequent cause of death in noncoronary intensive care units. In the past 10 years, progress has been made in the early identification of septic patients and their treatment. These improvements in support and therapy mean that mortality is gradually decreasing, however, the rate of death from sepsis remains unacceptably high. Immunotherapy is not currently part of the routine treatment of sepsis. Despite experimental successes, the administration of agents to block the effect of sepsis mediators failed to show evidence for improved outcome in a multitude of clinical trials. The following survey summarizes the current knowledge and results of clinical trials on the immunotherapy of sepsis and describes the limitations of our knowledge of the pathogenesis of sepsis. Administration of immunomodulatory drugs should be linked to the current immune status assessed by both clinical and molecular patterns. Thus, a careful daily review of the patient&apos;s immune status needs to be introduced into routine clinical practice giving the opportunity for effective and tailored use of immunomodulatory therapy.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30102 - Immunology

Projekt

—

Návaznosti

V - Vyzkumna aktivita podporovana z jinych verejnych zdroju

Rok uplatnění

2017

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Archivum Immunologiae et Therapiae Experimentalis

ISSN

0004-069X

e-ISSN

—

Svazek periodika

65

Číslo periodika v rámci svazku

1

Stát vydavatele periodika

CH - Švýcarská konfederace

Počet stran výsledku

13

Strana od-do

37-49

Kód UT WoS článku

000397235200004

EID výsledku v databázi Scopus

2-s2.0-84983410462